guest ::
| Home > Publications database > Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease > print |
| Home > Publications database > Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease > print |
| 001 | 892447 | ||
| 005 | 20210831151939.0 | ||
| 024 | 7 | _ | |a 10.1002/mds.28608 |2 doi |
| 024 | 7 | _ | |a 0885-3185 |2 ISSN |
| 024 | 7 | _ | |a 1531-8257 |2 ISSN |
| 024 | 7 | _ | |a 2128/28566 |2 Handle |
| 024 | 7 | _ | |a altmetric:105260253 |2 altmetric |
| 024 | 7 | _ | |a pmid:33942926 |2 pmid |
| 024 | 7 | _ | |a WOS:000646650300001 |2 WOS |
| 037 | _ | _ | |a FZJ-2021-02085 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Kremer, Thomas |0 P:(DE-HGF)0 |b 0 |e Corresponding author |
| 245 | _ | _ | |a Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease |
| 260 | _ | _ | |a New York, NY |c 2021 |b Wiley |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1629455611_14502 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Background: Cerebrospinal fluid (CSF) levels of monoamine metabolites may represent biomarkers of Parkinson's disease (PD).Objective: The aim of this study was quantification of multiple metabolites in CSF from PD versus healthy control subjects (HCs), including longitudinal analysis.Methods: Absolute levels of multiple monoamine metabolites in CSF were quantified by liquid chromatography coupled with tandem mass spectrometry from 161 individuals with early PD and 115 HCs from the Parkinson's Progression Marker Initiative and de novo PD (DeNoPA) studies.Results: Baseline levels of homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC) were lower in individuals with PD compared with HCs. HVA levels correlated with Movement Disorder Society Unified Parkinson's Disease Rating Scale total scores (P < 0.01). Both HVA/dopamine and DOPAC/dopamine levels correlated with caudate nucleus and raw DOPAC with putamen dopamine transporter single-photon emission computed tomography uptake ratios (P < 0.01). No metabolite changed over 2 years in drug-naive individuals, but some changed on starting levodopa treatment.Conclusions: HVA and DOPAC CSF levels mirrored nigrostriatal pathway damage, confirming the central role of dopaminergic degeneration in early PD. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.Keywords: CSF; Parkinson's disease; biomarker; catecholamine; homovanillic acid; monoamine metabolites; neurotransmitter. |
| 536 | _ | _ | |a 525 - Decoding Brain Organization and Dysfunction (POF4-525) |0 G:(DE-HGF)POF4-525 |c POF4-525 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to DataCite |
| 700 | 1 | _ | |a Taylor, Kirsten I. |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Siebourg-Polster, Juliane |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Gerken, Thomas |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Staempfli, Andreas |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Czech, Christian |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Dukart, Juergen |0 P:(DE-Juel1)177772 |b 6 |
| 700 | 1 | _ | |a Galasko, Douglas |0 P:(DE-HGF)0 |b 7 |
| 700 | 1 | _ | |a Foroud, Tatiana |0 P:(DE-HGF)0 |b 8 |
| 700 | 1 | _ | |a Chahine, Lana M. |0 P:(DE-HGF)0 |b 9 |
| 700 | 1 | _ | |a Coffey, Christopher S. |0 P:(DE-HGF)0 |b 10 |
| 700 | 1 | _ | |a Simuni, Tanya |0 P:(DE-HGF)0 |b 11 |
| 700 | 1 | _ | |a Weintraub, Daniel |0 P:(DE-HGF)0 |b 12 |
| 700 | 1 | _ | |a Seibyl, John |0 P:(DE-HGF)0 |b 13 |
| 700 | 1 | _ | |a Poston, Kathleen L. |0 P:(DE-HGF)0 |b 14 |
| 700 | 1 | _ | |a Toga, Arthur W. |0 P:(DE-HGF)0 |b 15 |
| 700 | 1 | _ | |a Tanner, Caroline M. |0 P:(DE-HGF)0 |b 16 |
| 700 | 1 | _ | |a Marek, Kenneth |0 P:(DE-HGF)0 |b 17 |
| 700 | 1 | _ | |a Hutten, Samantha J. |0 P:(DE-HGF)0 |b 18 |
| 700 | 1 | _ | |a Dziadek, Sebastian |0 P:(DE-HGF)0 |b 19 |
| 700 | 1 | _ | |a Trenkwalder, Claudia |0 P:(DE-HGF)0 |b 20 |
| 700 | 1 | _ | |a Pagano, Gennaro |0 P:(DE-HGF)0 |b 21 |
| 700 | 1 | _ | |a Mollenhauer, Brit |0 P:(DE-HGF)0 |b 22 |
| 773 | _ | _ | |a 10.1002/mds.28608 |g p. mds.28608 |0 PERI:(DE-600)2041249-6 |n 8 |p 1972-1978 |t Movement disorders |v 36 |y 2021 |x 1531-8257 |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/892447/files/mds.28608.pdf |y OpenAccess |
| 909 | C | O | |o oai:juser.fz-juelich.de:892447 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 6 |6 P:(DE-Juel1)177772 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-525 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Decoding Brain Organization and Dysfunction |x 0 |
| 913 | 0 | _ | |a DE-HGF |b Key Technologies |l Decoding the Human Brain |1 G:(DE-HGF)POF3-570 |0 G:(DE-HGF)POF3-572 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-500 |4 G:(DE-HGF)POF |v (Dys-)function and Plasticity |x 0 |
| 914 | 1 | _ | |y 2021 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2021-01-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2021-01-30 |
| 915 | _ | _ | |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0 |0 LIC:(DE-HGF)CCBYNCND4 |2 HGFVOC |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b MOVEMENT DISORD : 2019 |d 2021-01-30 |
| 915 | _ | _ | |a DEAL Wiley |0 StatID:(DE-HGF)3001 |2 StatID |d 2021-01-30 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2021-01-30 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2021-01-30 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2021-01-30 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b MOVEMENT DISORD : 2019 |d 2021-01-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2021-01-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2021-01-30 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2021-01-30 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2021-01-30 |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-7-20090406 |k INM-7 |l Gehirn & Verhalten |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)INM-7-20090406 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|